Point mutation screening of tumor neoantigens and peptide‑induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database

Wu,Wanwen; Chen,Ying; Huang,Lan; Li,Wenjian; Tao,Changli; Shen,Han

doi:10.3892/ol.2020.11986

Point mutation screening of tumor neoantigens and peptide‑induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database

Authors:
- Wanwen Wu
- Ying Chen
- Lan Huang
- Wenjian Li
- Changli Tao
- Han Shen
View Affiliations

Affiliations: Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China
Published online on: August 19, 2020 https://doi.org/10.3892/ol.2020.11986
Article Number: 123
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to use The Cancer Genome Atlas (TCGA) database to identify tumor neoantigens, combined with a bioinformatics analysis to design and analyze antigen epitope peptides. Epitopes were screened using immunogenicity tests to identify the ideal epitope peptides to target tumor neoantigens, which can specifically activate the immune response of T cells. The high‑frequency mutation loci (top 10) of colorectal, lung and liver cancer genes were screened using TCGA database. The antigenic epitope peptides with high affinity for major histocompatibility complex molecules were selected and synthesized using computer prediction algorithms, and were subsequently detected using flow cytometry. The cytotoxicity of specific cytotoxic T lymphocytes (CTLs) on peptide‑loaded T2 cells was initially verified using interferon IFN‑γ detection and a calcein‑acetoxymethyl (Cal‑AM) release assay. Tumor cell lines expressing point mutations in KRAS, TP53 and CTNNB1 genes were constructed respectively, and the cytotoxicity of peptide‑induced specific CTLs on wild‑type and mutant tumor cells was verified using a Cal‑AM release assay and carboxyfluorescein succinimidyl ester‑propidium iodide staining. The high‑frequency gene mutation loci of KRAS proto‑oncogene (KRAS) G12V, tumor protein p53 (TP53) R158L and catenin β1 (CTNNB1) K335I were identified in TCGA database. A total of 3 groups of wild‑type and mutant peptides were screened using a peptide prediction algorithm. The CTNNB1 group had a strong affinity for the human leukocyte antigen‑A2 molecule, as determined using flow cytometry. The IFN‑γ secretion of specific CTLs in the CTNNB1 group was the highest, followed by the TP53 and the KRAS groups. The killing rate of mutant peptide‑induced specific CTLs on peptide‑loaded T2 cells in the CTNNB1 group was higher compared with that observed in the other groups. The killing rate of specific CTLs induced by mutant peptides present on tumor cells was higher compared with that induced by wild‑type peptides. However, when compared with the TP53 and KRAS groups, specific CTLs induced by mutant peptides in the CTNNB1 group had more potent cytotoxicity towards mutant and wild‑type tumor cells. In conclusion, point mutant tumor neoantigens screened in the three groups improved the cytotoxicity of specific T cells, and the mutant peptides in the CTNNB1 group were more prominent, indicating that they may activate the cellular immune response more readily.

View Figures

View References

1	Efremova M, Finotello F, Rieder D and Trajanoski Z: Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol. 8:16792017. View Article : Google Scholar : PubMed/NCBI
2	Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, Ren S and Zhou C: Tumor neoantigens: From basic research to clinical applications. J Hematol Oncol. 12:932019. View Article : Google Scholar : PubMed/NCBI
3	Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, et al: Neoantigen vaccine: An emerging tumor immunotherapy. Mol Cancer. 18:1282019. View Article : Google Scholar : PubMed/NCBI
4	Zhou C, Zhu C and Liu Q: Toward in silico identification of tumor neoantigens in immunotherapy. Trends Mol Med. 25:980–992. 2019. View Article : Google Scholar : PubMed/NCBI
5	Garcia-Garijo A, Fajardo CA and Gros A: Determinants for neoantigen identification. Front Immunol. 10:13922019. View Article : Google Scholar : PubMed/NCBI
6	Wirth TC and Kühnel F: Neoantigen targeting-dawn of a new era in cancer immunotherapy? Front Immunol. 8:18482017. View Article : Google Scholar : PubMed/NCBI
7	Rammensee H, Bachmann J, Emmerich NP, Bachor OA and Stevanović S: SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics. 50:213–219. 1999. View Article : Google Scholar : PubMed/NCBI
8	Parker KC, Bednarek MA and Coligan JE: Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 152:163–175. 1994.PubMed/NCBI
9	Richters MM, Xia H, Campbell KM, Gillanders WE, Griffith OL and Griffith M: Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11:562019. View Article : Google Scholar : PubMed/NCBI
10	Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al: Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 350:1387–1390. 2015. View Article : Google Scholar : PubMed/NCBI
11	Carey MF, Peterson CL and Smale ST: PCR-mediated site-directed mutagenesis. Cold Spring Harb Protoc. 2013:738–742. 2013. View Article : Google Scholar : PubMed/NCBI
12	Mazzei M, Vascellari M, Zanardello C, Melchiotti E, Vannini S, Forzan M, Marchetti V, Albanese F and Abramo F: Quantitative real time polymerase chain reaction (qRT-PCR) and RNAscope in situ hybridization (RNA-ISH) as effective tools to diagnose feline herpesvirus-1-associated dermatitis. Vet Dermatol. 30:e491–e147. 2019. View Article : Google Scholar
13	Thaxton JE and Li Z: To affinity and beyond: Harnessing the T cell receptor for cancer immunotherapy. Hum Vaccin Immunother. 10:3313–3321. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kisielow P: How does the immune system learn to distinguish between good and evil? The first definitive studies of T cell central tolerance and positive selection. Immunogenetics. 71:513–518. 2019. View Article : Google Scholar : PubMed/NCBI
15	Schumacher TN and Schreiber RD: Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
16	Kanaseki T: Proteogenomics HLA Ligandome analysis for cancer antigen research. Gan To Kagaku Ryoho. 46:1377–1381. 2019.(In Japanese). PubMed/NCBI
17	Matsushita H, Demachi-Okamura A and Takahashi Y: Neoantigens are critical targets in naturally and therapeutically induced immune responses to cancer. Gan To Kagaku Ryoho. 46:1372–1376. 2019.(In Japanese). PubMed/NCBI
18	Garrido F and Aptsiauri N: Cancer immune escape: MHC expression in primary tumors versus metastases. Immunology. 158:255–266. 2019. View Article : Google Scholar : PubMed/NCBI
19	Mandal R and Chan TA: Personalized oncology meets immunology: The path toward precision immunotherapy. Cancer Discov. 6:703–713. 2016. View Article : Google Scholar : PubMed/NCBI
20	Wang Z, Jensen MA and Zenklusen JC: A practical guide to the cancer genome atlas (TCGA). Methods Mol Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
21	Lu YC and Robbins PF: Cancer immunotherapy targeting neoantigens. Semin Immunol. 28:22–27. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ren L, Leisegang M, Deng B, Matsuda T, Kiyotani K, Kato T, Harada M, Park JH, Saloura V, Seiwert T, et al: Identification of neoantigen-specific T cells and their targets: Implications for immunotherapy of head and neck squamous cell carcinoma. Oncoimmunology. 8:e15688132019. View Article : Google Scholar : PubMed/NCBI
23	Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ, He QM, Yang XJ, Sun Y, Mao YP, Yun JP, et al: Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: Immunotherapeutic implications. Theranostics. 7:3585–3594. 2017. View Article : Google Scholar : PubMed/NCBI
24	Vormehr M, Diken M, Türeci Ö, Sahin U and Kreiter S: Personalized neo-epitope vaccines for cancer treatment. Recent Results Cancer Res. 214:153–167. 2020. View Article : Google Scholar : PubMed/NCBI
25	Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547:217–221. 2017. View Article : Google Scholar : PubMed/NCBI
26	Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, et al: Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 565:234–239. 2019. View Article : Google Scholar : PubMed/NCBI
27	Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, et al: Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun. 10:4492019. View Article : Google Scholar : PubMed/NCBI
28	Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 344:641–645. 2014. View Article : Google Scholar : PubMed/NCBI
29	Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al: T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 375:2255–2262. 2016. View Article : Google Scholar : PubMed/NCBI
30	Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al: Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 24:724–730. 2018. View Article : Google Scholar : PubMed/NCBI
31	Shindo Y, Hazama S and Nagano H: Cancer vaccine focused on neoantigens. Gan To Kagaku Ryoho. 46:1367–1371. 2019.(In Japanese). PubMed/NCBI
32	Chu Y, Liu Q, Wei J and Liu B: Personalized cancer neoantigen vaccines come of age. Theranostics. 8:4238–4246. 2018. View Article : Google Scholar : PubMed/NCBI
33	Zhou J, Zhao W, Wu J, Lu J, Ding Y, Wu S, Wang H, Ding D, Mo F, Zhou Z, et al: Neoantigens derived from recurrently mutated genes as potential immunotherapy targets for gastric cancer. Biomed Res Int. 2019:81031422019. View Article : Google Scholar : PubMed/NCBI
34	Vilimas T: Measuring tumor mutational burden using whole-exome sequencing. Methods Mol Biol. 2055:63–91. 2020. View Article : Google Scholar : PubMed/NCBI
35	Smith CC, Chai S, Washington AR, Lee SJ, Landoni E, Field K, Garness J, Bixby LM, Selitsky SR, Parker JS, et al: Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes. Cancer Immunol Res. 7:1591–1604. 2019. View Article : Google Scholar : PubMed/NCBI
36	Riley TP, Keller GLJ, Smith AR, Davancaze LM, Arbuiso AG, Devlin JR and Baker BM: Structure based prediction of neoantigen immunogenicity. Front Immunol. 10:20472019. View Article : Google Scholar : PubMed/NCBI
37	Brennick CA, George MM, Corwin WL, Srivastava PK and Ebrahimi-Nik H: Neoepitopes as cancer immunotherapy targets: Key challenges and opportunities. Immunotherapy. 9:361–371. 2017. View Article : Google Scholar : PubMed/NCBI